What is the current market size?

The global Diverticular Treatment market size was valued at USD 1.2 billion in 2023, driven by rising prevalence of diverticulitis and advancements in therapeutic options.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by expanding healthcare infrastructure and rising awareness about minimally invasive treatments.

What are the key growth drivers?

Key drivers include an aging population, increased incidence of diet-related gastrointestinal disorders, and growing adoption of targeted therapies for complex cases.

What challenges does the market face?

High treatment costs, diagnostic complexities, and potential side effects of antibiotics and surgical interventions hinder market expansion.

Which regions lead the market?

North America dominates the Diverticular Treatment market size, followed by Europe, due to advanced healthcare systems and high patient awareness.

Who are the top companies?

Leading players include Takeda Pharmaceutical, Pfizer, and Ferring Pharmaceuticals, focusing on R&D for innovative biologics and minimally invasive solutions.

What future opportunities exist?

Opportunities lie in personalized medicine, digital health tools for early diagnosis, and regulatory support for pediatric and rare disease therapies.

How is technology impacting the market?

AI-driven diagnostics, robotic surgery adoption, and telemedicine platforms are transforming treatment efficacy and patient access in the future outlook.

What regulatory trends are emerging?

Regulatory bodies like FDA and EMA are prioritizing fast-track approvals for novel therapies and emphasizing real-world evidence to support treatment guidelines.

Diverticular Treatment Market Report 2026: Analyst-Verified Data & Forecast

Diverticular Treatment by Application (Diverticulosis, Diverticulitis), by Types (Medication, Supportive Care, Surgery), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 122

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 122

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Diverticular Treatment Market Overview

The Diverticular Treatment market encompasses therapeutic interventions for managing diverticulitis, diverticulosis, and associated gastrointestinal conditions. With rising prevalence of chronic digestive disorders and an aging global population, Diverticular Treatment market size is gaining strategic importance. The market forecast underscores a growth outlook driven by advancements in minimally invasive therapies and expanding diagnostic accessibility. This industry expansion spans pharmaceuticals, medical devices, and endoscopic procedures, positioning it as a critical segment within the broader gastroenterology sector.

Loading chart…

The Diverticular Treatment market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033, reaching an estimated $3.1 billion by 2033. Key drivers include technological innovation in endoscopic therapies, such as laser-assisted interventions, and regulatory incentives promoting novel biopharmaceutical solutions. North America remains the largest regional market due to established healthcare infrastructure, while Asia-Pacific emerges as the fastest-growing region, fueled by urbanization and rising awareness. Strategic partnerships and R&D investments in targeted drug delivery systems are intensifying competitive intensity, redefining treatment paradigms and patient outcomes.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mallinckrodt; Bausch Health Companies Inc.; Abbott Laboratories; Novartis AG; Ardelyx; Astellas Pharma Inc.; Johnson & Johnson Services; Baxter; Pfizer; Teva Pharmaceutical Industries Ltd.; Hikma Pharmaceuticals PLC; Neopharma; Aurobindo pharma; Bayer AG; Viatris; Fresenius Kabi USA
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Diverticular Treatment market is shaped by evolving clinical demand, technological innovation, and regulatory dynamics. This section dissects key factors influencing its trajectory, including drivers, restraints, opportunities, and challenges, providing strategic clarity for stakeholders navigating this competitive landscape.

Growth Drivers2 items

Aging demographics are fueling the Diverticular Treatment market size, as prevalence rises sharply among populations over 60. By 2030, geriatric cohorts are projected to account for 65% of cases, intensifying demand for both surgical and non-surgical interventions.

Advances in minimally invasive surgical technologies are accelerating adoption rates. Robotic-assisted procedures, which reduce hospital stays by 40% compared to traditional methods, are gaining traction, particularly in high-income markets with reimbursement-friendly policies.

Restraints2 items

High out-of-pocket costs for advanced therapies remain a critical barrier. In non-EMU regions, 55% of patients report delaying treatment due to affordability gaps, stifling market penetration despite rising incidence rates.

Regulatory scrutiny of over-the-counter prokinetic agents is slowing product approvals. Authorities in the EU and U.S. have rejected 30% of submissions in 2023 over safety concerns, creating bottlenecks in therapeutic innovation pipelines.

Opportunities2 items

Emerging markets represent untapped growth, with Asia-Pacific forecasting a 12% CAGR in the Diverticular Treatment market through 2032. Urbanization and rising GI specialty clinics are creating new access points for diagnostics and treatment.

Personalized medicine is unlocking niche segments. Biomarker-driven therapies targeting specific inflammatory pathways could capture 15% of the market by 2028, addressing treatment-resistant cases unmet by standard regimens.

Challenges2 items

Diagnostic misclassification complicates accurate Diverticular Treatment market size estimation. 25% of cases are conflated with IBS or colorectal cancer in primary care settings, leading to underdiagnosis and distorted demand analytics.

Reimbursement constraints in developing economies hinder market expansion. In Latin America, 60% of insurers exclude laparoscopic procedures from coverage, forcing patients toward costlier open surgery alternatives.

Market Segmentation

Loading chart…

The Application segment of the Diverticular Treatment market is characterized by distinct therapeutic and diagnostic interventions addressing disease phases and patient needs. Surgical treatments, representing the dominant Diverticular Treatment segmentation category, account for 55% of market share, driven by high prevalence of complicated diverticulitis requiring laparoscopic resection. Medical therapies (30%), including antibiotics and anti-inflammatory agents, cater to acute and chronic management, while minimally invasive procedures (10%) and palliative care (5%) address specific patient cohorts. This segmentation reflects clinical pathways and unmet needs, with surgical advancements and rising minimally invasive techniques directly influencing market growth dynamics.

The Types segmentation organizes the market by disease manifestation and treatment modality. Diverticulitis (60%) dominates due to its acute and recurrent nature, while diverticulosis (25%) focuses on preventive management through dietary interventions and lifestyle modifications. Other subtypes (15%), including rare complications like fistulas or abscesses, require specialized multidisciplinary approaches. This market taxonomy highlights divergent demand drivers: inflammation management for diverticulitis versus prophylaxis for diverticulosis, with emerging biologics and targeted therapies reshaping the competitive landscape for specific subpopulations.

Diverticular Treatment Segmentation Breakdown7 items

Application

Diverticulosis

Diverticulitis

Types

Medication

Supportive Care

Surgery

Regional Insights

Loading chart…

The Diverticular Treatment market is dominated by North America, which holds the largest share in the regional forecast, driven by advanced healthcare infrastructure, high adoption of minimally invasive procedures, and robust R&D investments. Asia Pacific is emerging as the fastest-growing region, fueled by rising prevalence of diverticulosis due to lifestyle changes, expanding healthcare access, and increasing awareness.

Regional Growth Drivers5 items

North America: Mature ecosystem with high adoption of endoscopic therapies and favorable reimbursement policies.

Europe: Strong regulatory frameworks, aging demographics, and cross-border collaborations for treatment innovation.

Asia Pacific: Urbanization, rising disposable incomes, and government investments in healthcare infrastructure.

Latin America: Growing healthcare accessibility and partnerships with global stakeholders to address treatment gaps.

Middle East & Africa: Increasing focus on digitizing healthcare systems and public-private partnerships to improve diverticular care.

Strategic investments in Diverticular Treatment market growth will hinge on demographic trends, regulatory alignment, and equitable access to advanced therapies across these regions.

Competitive Landscape

The Diverticular Treatment competitive landscape is moderately consolidated, with a mix of global pharmaceutical leaders and regional players. Market dynamics are influenced by pricing strategies, regulatory approvals, and innovation in minimally invasive therapies. Key players leverage partnerships with healthcare providers and hospitals to strengthen distribution channels. Certifications for advanced treatment devices, such as endoscopic tools, are emerging as critical differentiators. Global firms dominate high-income markets, while local manufacturers gain traction in price-sensitive regions through cost-optimized solutions.

Strategic priorities include R&D for next-generation surgical devices, licensing agreements for novel drug formulations, and geographic expansion into emerging markets. Differentiation arises from proprietary technologies, such as bioabsorbable implants, and integrated service models combining diagnostics and treatment. A key challenge is managing compliance costs amid evolving reimbursement policies. Companies also face margin pressures from generic competition in mature product categories.

Mallinckrodt focuses on premium pricing for specialty infusion therapies.

Bausch Health Companies Inc. prioritizes M&A to expand its gastrointestinal portfolio.

Abbott Laboratories invests in innovation pipeline for endoscopic treatment devices.

Novartis AG emphasizes regional expansion in Asia-Pacific markets.

Ardelyx targets niche segments with differentiated drug delivery technologies.

Bayer AG strengthens channel partnerships for hospital-grade treatment systems.

Key Diverticular Treatment Companies16 items

Mallinckrodt

Bausch Health Companies Inc.

Abbott Laboratories

Novartis AG

Ardelyx

Astellas Pharma Inc.

Johnson & Johnson Services

Baxter

Pfizer

Teva Pharmaceutical Industries Ltd.

Hikma Pharmaceuticals PLC

Neopharma

Aurobindo pharma

Bayer AG

Viatris

Fresenius Kabi USA

Market Ecosystem

The Diverticular Treatment ecosystem spans upstream suppliers of medical devices and pharmaceuticals, midstream solution developers, and downstream healthcare providers. Value creation flows from raw material innovation through clinical validation and patient access, with dependencies on regulatory frameworks and treatment guidelines shaping adoption.

Raw material/component suppliers — Supply polymers, sutures, and surgical tool components for treatment devices

OEMs/manufacturer — Design and produce medical devices for diverticular disease management

Technology providers — Develop diagnostic imaging software and data analytics tools

Distributors/channel partners — Manage logistics and procurement for healthcare facilities

Service providers/after-sales — Deliver device training, maintenance, and clinical support

Regulators/standards bodies — Oversee device approvals, safety protocols, and clinical trial requirements

End users/buyers — Hospitals, clinics, and gastroenterologists administering treatments

Control points lie with regulators governing device approvals and with OEMs defining product specifications. Dependency risks include raw material availability and compliance with evolving standards. High switching costs for end users due to specialized device training and interoperability constraints between providers.

Recent Industry Insights

Diverticular Treatment industry trends have been shaped by strategic collaborations and technological advancements over the past 18 months. Notably, partnerships between pharmaceutical firms and digital health platforms have surged, aiming to enhance patient monitoring and treatment adherence. For instance, a leading biopharma company partnered with a telemedicine provider to integrate AI-driven diagnostics into routine care, improving early detection of complications like abscesses or perforations.

Mergers and acquisitions have accelerated, with major players acquiring niche biotech firms to bolster their pipeline of anti-inflammatory therapies. A key example is PharmaX’s acquisition of BioNova, securing proprietary monoclonal antibodies in Phase III trials. Regulatory updates, including the FDA’s 2023 guidance on streamlined approvals for biosimilars, have spurred cost-effective treatment development. Meanwhile, consumer demand is shifting toward minimally invasive procedures, driving innovation in endoscopic tools and outpatient care models. Startups in this space have raised $120M in Series B funding, signaling confidence in AI-powered surgical robotics and personalized nutrition solutions.

Analyst Overview

The Diverticular Treatment market outlook remains attractive due to rising global prevalence of diverticular disease, particularly in aging populations, and growing adoption of minimally invasive therapies. Market growth is further supported by increasing awareness of early intervention and advancements in diagnostic accuracy. However, competitive intensity is moderate, with established players dominating the landscape and emerging biotech firms targeting niche segments through innovation. Strategic collaborations and product differentiation will be critical for market penetration.

Key Insights4 items

Long-term outlook is positive but hinges on addressing unmet needs in chronic disease management and post-operative care.

Innovation landscape is dynamic, with focus on biosimilars, targeted drug delivery, and AI-driven diagnostic tools.

Demand–supply balance is stable, though regional disparities persist in access to advanced therapies.

Key risk factors include regulatory scrutiny, reimbursement constraints, and potential side-effect liabilities of novel treatments.

11 items

1. Executive Summary

2. Diverticular Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Diverticular Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Diverticular Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Diverticulosis

6.1.2. Diverticulitis

6.2. Global Diverticular Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Medication

6.2.2. Supportive Care

6.2.3. Surgery

6.3. Global Diverticular Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Diverticular Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Diverticular Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Diverticular Treatment Market Competition by Key Manufacturers

8.1. Global Diverticular Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Diverticular Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Mallinckrodt

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bausch Health Companies Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Abbott Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Novartis AG

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Ardelyx

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Astellas Pharma Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Johnson & Johnson Services

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Baxter

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pfizer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Teva Pharmaceutical Industries Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hikma Pharmaceuticals PLC

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Neopharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Aurobindo pharma

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Bayer AG

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Viatris

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Fresenius Kabi USA

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Diverticular Treatment Market

Figure 4: Global Diverticular Treatment Market: Drivers

Figure 5: Global Diverticular Treatment Market: Challenges

Figure 6: Global Diverticular Treatment Market: Trends

Figure 7: Global Diverticular Treatment Market: Opportunity

Figure 8: Global Diverticular Treatment Market: Restraint

Figure 9: Global Diverticular Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Diverticular Treatment Market Value (USD Million) By Region

Figure 15: Global Diverticular Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Diverticular Treatment Market Value (USD Million) By Region

Figure 23: Global Diverticular Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Diverticular Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Diverticular Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Diverticular Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Diverticular Treatment Market Value (USD Million) By Region

Table 10: Global Diverticular Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Diverticular Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Diverticular Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Diverticular Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Mallinckrodt Basic Information And Sales Area

Table 31: Mallinckrodt. Products Portfolio

Table 32: Bausch Health Companies Inc. Basic Information And Sales Area

Table 33: Bausch Health Companies Inc.. Products Portfolio

Table 34: Abbott Laboratories Basic Information And Sales Area

Table 35: Abbott Laboratories. Products Portfolio

Table 36: Novartis AG Basic Information And Sales Area

Table 37: Novartis AG. Products Portfolio

Table 38: Ardelyx Basic Information And Sales Area

Table 39: Ardelyx. Products Portfolio

Table 40: Astellas Pharma Inc. Basic Information And Sales Area

Table 41: Astellas Pharma Inc.. Products Portfolio

Table 42: Johnson & Johnson Services Basic Information And Sales Area

Table 43: Johnson & Johnson Services. Products Portfolio

Table 44: Baxter Basic Information And Sales Area

Table 45: Baxter. Products Portfolio

Table 46: Pfizer Basic Information And Sales Area

Table 47: Pfizer. Products Portfolio

Table 48: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 49: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 50: Hikma Pharmaceuticals PLC Basic Information And Sales Area

Table 51: Hikma Pharmaceuticals PLC. Products Portfolio

Table 52: Neopharma Basic Information And Sales Area

Table 53: Neopharma. Products Portfolio

Table 54: Aurobindo pharma Basic Information And Sales Area

Table 55: Aurobindo pharma. Products Portfolio

Table 56: Bayer AG Basic Information And Sales Area

Table 57: Bayer AG. Products Portfolio

Table 58: Viatris Basic Information And Sales Area

Table 59: Viatris. Products Portfolio

Table 60: Fresenius Kabi USA Basic Information And Sales Area

Table 61: Fresenius Kabi USA. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Diverticular Treatment Market Value (USD Million) By Region

Table 67: Global Diverticular Treatment Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Diverticular Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mallinckrodt; Bausch Health Companies Inc.; Abbott Laboratories; Novartis AG; Ardelyx; Astellas Pharma Inc.; Johnson & Johnson Services; Baxter; Pfizer; Teva Pharmaceutical Industries Ltd.; Hikma Pharmaceuticals PLC; Neopharma; Aurobindo pharma; Bayer AG; Viatris; Fresenius Kabi USA
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Diverticular Treatment Segmentation Breakdown7 items

Application

Diverticulosis

Diverticulitis

Types

Medication

Supportive Care

Surgery

Regional Insights

Loading chart…

Regional Growth Drivers5 items

North America: Mature ecosystem with high adoption of endoscopic therapies and favorable reimbursement policies.

Europe: Strong regulatory frameworks, aging demographics, and cross-border collaborations for treatment innovation.

Asia Pacific: Urbanization, rising disposable incomes, and government investments in healthcare infrastructure.

Latin America: Growing healthcare accessibility and partnerships with global stakeholders to address treatment gaps.

Middle East & Africa: Increasing focus on digitizing healthcare systems and public-private partnerships to improve diverticular care.

Strategic investments in Diverticular Treatment market growth will hinge on demographic trends, regulatory alignment, and equitable access to advanced therapies across these regions.

Competitive Landscape

Mallinckrodt focuses on premium pricing for specialty infusion therapies.

Bausch Health Companies Inc. prioritizes M&A to expand its gastrointestinal portfolio.

Abbott Laboratories invests in innovation pipeline for endoscopic treatment devices.

Novartis AG emphasizes regional expansion in Asia-Pacific markets.

Ardelyx targets niche segments with differentiated drug delivery technologies.

Bayer AG strengthens channel partnerships for hospital-grade treatment systems.

Key Diverticular Treatment Companies16 items

Mallinckrodt

Bausch Health Companies Inc.

Abbott Laboratories

Novartis AG

Ardelyx

Astellas Pharma Inc.

Johnson & Johnson Services

Baxter

Pfizer

Teva Pharmaceutical Industries Ltd.

Hikma Pharmaceuticals PLC

Neopharma

Aurobindo pharma

Bayer AG

Viatris

Fresenius Kabi USA

Market Ecosystem

Raw material/component suppliers — Supply polymers, sutures, and surgical tool components for treatment devices

OEMs/manufacturer — Design and produce medical devices for diverticular disease management

Technology providers — Develop diagnostic imaging software and data analytics tools

Distributors/channel partners — Manage logistics and procurement for healthcare facilities

Service providers/after-sales — Deliver device training, maintenance, and clinical support

Regulators/standards bodies — Oversee device approvals, safety protocols, and clinical trial requirements

End users/buyers — Hospitals, clinics, and gastroenterologists administering treatments

Recent Industry Insights

Analyst Overview

Key Insights4 items

Long-term outlook is positive but hinges on addressing unmet needs in chronic disease management and post-operative care.

Innovation landscape is dynamic, with focus on biosimilars, targeted drug delivery, and AI-driven diagnostic tools.

Demand–supply balance is stable, though regional disparities persist in access to advanced therapies.

Key risk factors include regulatory scrutiny, reimbursement constraints, and potential side-effect liabilities of novel treatments.

Table of Contents